Home LiteratureArticle Details
PMID: 14512572 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Journal of virology ·Vol. 77 ·No. 20 ·2003-10-00 ·Pages 11244-59

Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S, Martin L, Vita C, Zhu P, Roux KH, Vojtech L, C Montefiori D, Donnelly J, Ulmer JB, Barnett SW

Abstract

The envelope (Env) glycoprotein of human immunodeficiency virus type 1 (HIV-1) is the major target of neutralizing antibody responses and is likely to be a critical component of an effective vaccine against AIDS. Although monomeric HIV envelope subunit vaccines (gp120) have induced high-titer antibody responses and neutralizing antibodies against laboratory-adapted HIV-1 strains, they have failed to induce neutralizing antibodies against diverse heterologous primary HIV isolates. Most probably, the reason for this failure is that the antigenic structure(s) of these previously used immunogens does not mimic that of the functional HIV envelope, which is a trimer, and thus these immunogens do not elicit high titers of relevant functional antibodies. We recently reported that an Env glycoprotein immunogen (o-gp140SF162DeltaV2) containing a partial deletion in the second variable loop (V2) derived from the R5-tropic HIV-1 isolate SF162, when used in a DNA priming-protein boosting vaccine regimen in rhesus macaques, induced neutralizing antibodies against heterologous subtype B primary isolates as well as protection to the vaccinated animals upon challenge with pathogenic SHIV(SF162P4) virus. Here we describe the purification of this protein to homogeneity, its characterization as trimer, and its ability to induce primary isolate-neutralizing responses in rhesus macaques. Optimal mutations in the primary and secondary protease cleavage sites of the env gene were identified that resulted in the stable secretion of a trimeric Env glycoprotein in mammalian cell cultures. We determined the molecular mass and hydrodynamic radius (R(h)) using a triple detector analysis (TDA) system. The molecular mass of the oligomer was found to be 324 kDa, close to the expected M(w) of a HIV envelope trimer protein (330 kDa), and the hydrodynamic radius was 7.27 nm. Negative staining electron microscopy of o-gp140SF162DeltaV2 showed that it is a trimer with considerable structural flexibility and supported the data obtained by TDA. The structural integrity of the purified trimeric protein was also confirmed by determinations of its ability to bind the HIV receptor, CD4, and its ability to bind a panel of well-characterized neutralizing monoclonal antibodies. No deleterious effect of V2 loop deletion was observed on the structure and conformation of the protein, and several critical neutralization epitopes were preserved and well exposed on the purified o-gp140SF162DeltaV2 protein. In an intranasal priming and intramuscular boosting regimen, this protein induced high titers of functional antibodies, which neutralized the vaccine strain, i.e., SF162. These results highlight a potential role for the trimeric o-gp140SF162DeltaV2 Env immunogen in a successful HIV vaccine.

MeSH Terms
Amino Acid Sequence Animals CD4 Antigens/metabolism CHO Cells Cricetinae Gene Products, env/chemistry,immunology,isolation & purification Glycosylation HIV-1/chemistry Humans Macaca mulatta Microscopy, Electron Molecular Sequence Data env Gene Products, Human Immunodeficiency Virus
Chemicals
CD4 Antigens Gene Products, env env Gene Products, Human Immunodeficiency Virus gp140 envelope protein, Human immunodeficiency virus 1
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
Srivastava Indresh K
Vaccines Research, Chiron Corporation, Emeryville, California 94608, USA.
Stamatatos Leonidas
Kan Elaine
Vajdy Michael
Lian Ying
Hilt Susan
Martin Loic
Vita Claudio
Zhu Ping
Roux Kenneth H
Vojtech Lucia
C Montefiori David
Donnelly John
Ulmer Jeffrey B
Barnett Susan W
References (92)
92 references, click to expand
  1. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
    J Virol. 1995 Jan;69(1):101-9 PMID: 7527081
  2. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
    J Virol. 1997 Dec;71(12):9808-12 PMID: 9371651
  3. Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.
    J Virol. 1998 Sep;72(9):7620-5 PMID: 9696864
  4. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
    J Virol. 2001 Jan;75(2):645-53 PMID: 11134278
  5. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization.
    AIDS Res Hum Retroviruses. 1998 May 1;14(7):591-7 PMID: 9591713
  6. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
    J Virol. 1997 Jun;71(6):4319-30 PMID: 9151820
  7. Negative-Stain Immunoelectron-Microscopic Analysis of Small Macromolecules of Immunologic Significance
    Methods. 1996 Oct;10(2):247-56 PMID: 8812677
  8. Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface.
    J Virol. 2002 Aug;76(15):7863-7 PMID: 12097599
  9. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
    J Virol. 2000 Jan;74(2):627-43 PMID: 10623724
  10. Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.
    J Virol. 2002 Oct;76(20):10299-306 PMID: 12239306
  11. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3099-104 PMID: 8610175
  12. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
    J Virol. 2002 Jun;76(11):5357-68 PMID: 11991964
  13. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.
    J Virol. 2002 Apr;76(7):3511-21 PMID: 11884575
  14. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS.
    J Virol. 1991 Dec;65(12):7025-31 PMID: 1942255
  15. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.
    J Virol. 1992 Jan;66(1):172-82 PMID: 1727480
  16. Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis.
    J Exp Med. 1989 Mar 1;169(3):807-22 PMID: 2538547
  17. Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells.
    Biomed Chromatogr. 1988 Nov;2(6):260-70 PMID: 2852980
  18. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Biotechnol Ther. 1991;2(1-2):63-89 PMID: 1726963
  19. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    J Virol. 2000 Aug;74(15):6769-76 PMID: 10888615
  20. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
    J Virol. 1994 Jan;68(1):469-84 PMID: 7504741
  21. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.
    Proc Natl Acad Sci U S A. 1990 Jan;87(2):648-52 PMID: 2300552
  22. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques.
    J Virol. 1992 Oct;66(10):5937-48 PMID: 1527847
  23. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    J Virol. 2001 Jun;75(12):5526-40 PMID: 11356960
  24. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.
    J Virol. 2001 Feb;75(3):1547-50 PMID: 11152527
  25. Model for intracellular folding of the human immunodeficiency virus type 1 gp120.
    J Virol. 1989 Feb;63(2):639-46 PMID: 2536098
  26. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 PMID: 6096719
  27. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):4821-8 PMID: 7518527
  28. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer.
    Virology. 1996 Apr 1;218(1):134-40 PMID: 8615015
  29. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    J Immunol. 1995 Oct 15;155(8):4100-10 PMID: 7561123
  30. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein.
    AIDS Res Hum Retroviruses. 1993 Jul;9(7):589-94 PMID: 8369163
  31. Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.
    Virology. 1999 Mar 30;256(1):54-63 PMID: 10087226
  32. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.
    J Virol. 2001 Jul;75(13):5721-9 PMID: 11390574
  33. Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions.
    Anal Biochem. 1996 Sep 5;240(2):155-66 PMID: 8811899
  34. Rapid characterization of protein molecular weights and hydrodynamic structures by quasielastic laser-light scattering.
    Biopolymers. 1976 Jul;15(7):1283-99 PMID: 949535
  35. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.
    J Virol. 2002 Mar;76(5):2075-86 PMID: 11836385
  36. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.
    J Virol. 1991 Jan;65(1):31-41 PMID: 1985202
  37. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?
    Nat Med. 2000 Feb;6(2):123-5 PMID: 10655088
  38. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.
    J Clin Microbiol. 1988 Feb;26(2):231-5 PMID: 3422647
  39. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
    AIDS. 1995;9 Suppl A:S117-36 PMID: 8819579
  40. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
    J Virol. 1999 Jul;73(7):5294-300 PMID: 10364275
  41. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.
    J Virol. 2001 Feb;75(3):1165-71 PMID: 11152489
  42. Specificity and inhibitory activity of antibodies to Plasmodium falciparum aldolase.
    J Immunol. 1990 Feb 15;144(4):1497-503 PMID: 2406342
  43. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.
    J Virol. 2000 May;74(10):4746-54 PMID: 10775613
  44. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
    Virology. 1994 Mar;199(2):431-8 PMID: 8122371
  45. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication.
    AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1129-39 PMID: 9737584
  46. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
    J Biol Chem. 1990 Jun 25;265(18):10373-82 PMID: 2355006
  47. Immunoelectron microscopy of idiotype-anti-idiotype complexes.
    Methods Enzymol. 1989;178:130-44 PMID: 2601621
  48. Codon usage limitation in the expression of HIV-1 envelope glycoprotein.
    Curr Biol. 1996 Mar 1;6(3):315-24 PMID: 8805248
  49. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
    J Virol. 2000 Mar;74(6):2628-35 PMID: 10684277
  50. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.
    J Virol. 1995 Oct;69(10):6191-8 PMID: 7545244
  51. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
    J Virol. 1998 Oct;72(10):7840-5 PMID: 9733820
  52. Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.
    J Immunol. 1986 Nov 1;137(9):2937-44 PMID: 2428879
  53. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    Science. 1998 Jun 19;280(5371):1884-8 PMID: 9632381
  54. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11699-703 PMID: 7972127
  55. Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions.
    FEBS Lett. 1996 Jan 29;379(2):171-6 PMID: 8635586
  56. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  57. Conformational studies of bovine alkaline phosphatase in hydrophobic interaction and size-exclusion chromatography with linear diode array and low-angle laser light scattering detection.
    J Chromatogr. 1988 Jun 17;442:29-52 PMID: 3417821
  58. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  59. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
    J Virol. 2002 Mar;76(6):2835-47 PMID: 11861851
  60. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
    Vaccine. 1997 Jun;15(8):869-73 PMID: 9234536
  61. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    AIDS. 1994 Nov;8(11):1622-3 PMID: 7848602
  62. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):767-8 PMID: 6083454
  63. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.
    Cell. 1987 Sep 11;50(6):975-85 PMID: 2441877
  64. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
    J Virol. 1997 Apr;71(4):2779-85 PMID: 9060632
  65. Determination of molecular weight of membrane proteins by the use of low-angle laser light scattering combined with high-performance gel chromatography in the presence of a non-ionic surfactant.
    Biochim Biophys Acta. 1983 Sep 28;747(3):291-7 PMID: 6225464
  66. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
    J Exp Med. 1995 Jul 1;182(1):185-96 PMID: 7540648
  67. Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development.
    AIDS Res Hum Retroviruses. 1993 Dec;9(12):1233-44 PMID: 8142140
  68. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
    J Virol. 2002 Sep;76(17):8875-89 PMID: 12163607
  69. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.
    J Virol. 2002 Aug;76(15):7760-76 PMID: 12097589
  70. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.
    J Virol. 2002 May;76(9):4634-42 PMID: 11932429
  71. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells.
    Nucleic Acids Res. 1991 Jul 25;19(14):3979-86 PMID: 1650459
  72. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    J Virol. 1994 May;68(5):3015-26 PMID: 7512157
  73. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    J Virol. 1996 Feb;70(2):753-62 PMID: 8551612
  74. Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein.
    J Acquir Immune Defic Syndr. 1989;2(2):163-9 PMID: 2649653
  75. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  76. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
    AIDS. 1999;13 Suppl A:S137-62 PMID: 10885772
  77. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.
    J Virol. 2000 Dec;74(23):11008-16 PMID: 11069996
  78. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    J Virol. 1999 May;73(5):4009-18 PMID: 10196297
  79. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.
    J Virol. 2000 Jun;74(12):5716-25 PMID: 10823881
  80. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    J Infect Dis. 1996 Feb;173(2):340-8 PMID: 8568294
  81. Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition.
    J Virol. 1998 Jan;72(1):209-17 PMID: 9420217
  82. Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae.
    Vaccine. 1987 Jun;5(2):90-101 PMID: 3300079
  83. gp120: Biologic aspects of structural features.
    Annu Rev Immunol. 2001;19:253-74 PMID: 11244037
  84. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.
    J Virol. 2000 Jun;74(11):5091-100 PMID: 10799583
  85. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
    Virology. 1995 Jan 10;206(1):713-7 PMID: 7530400
  86. The antibody response in HIV-1 infection.
    AIDS. 1997;11 Suppl A:S87-98 PMID: 9451972
  87. A role for carbohydrates in immune evasion in AIDS.
    Nat Med. 1998 Jun;4(6):679-84 PMID: 9623976
  88. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
    AIDS Res Hum Retroviruses. 2000 Jul 1;16(10):981-94 PMID: 10890360
  89. Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120.
    J Biol Chem. 1988 Aug 25;263(24):11760-7 PMID: 2841333
  90. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques.
    Immunol Lett. 2001 Nov 1;79(1-2):47-55 PMID: 11595289
  91. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
    Science. 1991 Oct 4;254(5028):105-8 PMID: 1718036
  92. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding.
    J Virol. 1993 Jan;67(1):584-8 PMID: 8416385
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2003-10-00
Pages
11244-59
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC224963
Subset
IM
Grants
NIAID NIH HHS · N0-AI-95367 · United States
NIAID NIH HHS · N0-AI-05396 · United States
NIAID NIH HHS · R01 AI047708 · United States
NIAID NIH HHS · R01 AI47708 · United States
NIAID NIH HHS · N01AI95367 · United States
NIAID NIH HHS · R21 AI50430-01 · United States
PHS HHS · R21 A144291 · United States
NIAID NIH HHS · N01AI05396 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com